본문으로 건너뛰기
← 뒤로

Online risk scores for pre- and postoperative prediction of early recurrence in hepatocellular carcinoma patients undergoing conversion liver resection after tyrosine kinase inhibitors and immune checkpoint inhibitors therapy.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2025 Vol.51(9) p. 110220

Lin KY, Liu HZ, Liu JW, Zhu XD, Pan YX, Shen SL, Zhang W, Jin RA, Han CY, Chen J, Zhang XY, Liang BY, Zhang YD, Ma J, Wang NY, Li DX, Xiong R, Li ZC, Li JD, Zhang ZB, Chen JH, Chen YF, Zheng L, Zhao L, Yin T, Li DY, Zhang L, Li XC, Huang ZY, Wen TF, Chen YJ, Peng T, Liang X, Song TQ, Kuang M, Xu L, Wang K, Sun HC, Zeng YY

📝 환자 설명용 한 줄

[BACKGROUND] Conversion therapy with tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) offers the potential for curative resection in unresectable hepatocellular carcinoma (HCC

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Lin KY, Liu HZ, et al. (2025). Online risk scores for pre- and postoperative prediction of early recurrence in hepatocellular carcinoma patients undergoing conversion liver resection after tyrosine kinase inhibitors and immune checkpoint inhibitors therapy.. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 51(9), 110220. https://doi.org/10.1016/j.ejso.2025.110220
MLA Lin KY, et al.. "Online risk scores for pre- and postoperative prediction of early recurrence in hepatocellular carcinoma patients undergoing conversion liver resection after tyrosine kinase inhibitors and immune checkpoint inhibitors therapy.." European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, vol. 51, no. 9, 2025, pp. 110220.
PMID 40544714

Abstract

[BACKGROUND] Conversion therapy with tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) offers the potential for curative resection in unresectable hepatocellular carcinoma (HCC). However, early recurrence (≤2 years) after conversion liver resection remains a major concern. This study aimed to develop and validate online preoperative and postoperative risk scores to predict early recurrence in patients undergoing conversion liver resection.

[METHODS] A total of 203 patients with initially unresectable HCC who underwent conversion liver resection following TKI and ICI therapy across 28 academic centers were analyzed. Independent predictors of early recurrence were identified using Cox proportional hazards analyses, and risk scores were developed and validated using the C-index, time-dependent AUC (tdAUC), and calibration curves.

[RESULTS] Preoperative risk score model included the neutrophil-to-lymphocyte ratio (NLR) ≥ 1.39, multiple tumors, absence of radiographic response, and no alpha-fetoprotein (AFP) response. Postoperative risk score model included NLR ≥1.39, multiple tumors, no AFP response, active macrovascular invasion, and incomplete pathological response. The preoperative risk score had a C-index of 0.699 (training) and 0.681 (validation), while the postoperative risk score had a C-index of 0.739 (training) and 0.706 (validation). Both models demonstrated good predictive accuracy through tdAUC and calibration curves. Decision tree analysis stratified patients into distinct risk categories with significant differences in 2-year recurrence rates. All risk score models are available online for clinical use.

[CONCLUSION] Online preoperative and postoperative risk scores provide valuable tools for predicting early recurrence in HCC patients after conversion liver resection, aiding in surgical decision-making and postoperative management.

MeSH Terms

Humans; Liver Neoplasms; Carcinoma, Hepatocellular; Male; Female; Protein Kinase Inhibitors; Neoplasm Recurrence, Local; Middle Aged; Hepatectomy; Immune Checkpoint Inhibitors; Risk Assessment; Aged; Retrospective Studies; Risk Factors; Neutrophils; Postoperative Period; Proportional Hazards Models; Tyrosine Kinase Inhibitors

같은 제1저자의 인용 많은 논문 (1)